Shanliang Sun holds a Bachelor’s and Master’s degree in Medicinal Chemistry from China Pharmaceutical University, and a Doctoral degree from Vrije Universiteit Amsterdam. He is currently employed at Nanjing University of Chinese Medicine. His primary focus is on the R&D of small molecule drugs, leveraging computer-assisted techniques. His work encompasses the de novo design of small molecule drugs targeting well-established targets such as kinases and GPCRs, as well as the identification and targeting of novel, independently discovered targets.